FibroGen, Inc.
FGENFibroGen, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2025, FibroGen was mainly reduced to a single early-stage oncology drug candidate.
Drugs in Pipeline
10
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Pancreatic Cancer Non-resectable
Epoetin Alfa
CKD Anemia in Stable Dialysis Patients
FG-4592
Anemia in Chronic Kidney Disease
SEPO®
Chemotherapy Induced Anemia
Roxadustat
Chronic Kidney Disease
Pamrevlumab
Idiopathic Pulmonary Fibrosis
FG2216
Renal Anemia
FG-3019
Pancreatic Cancer (Unresectable)
Oral Iron
Dialysis
FG-3246
Metastatic Castration-Resistant Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX | Phase 3 | Pancreatic Cancer Non-resectable | - | - |
Epoetin Alfa | Phase 3 | CKD Anemia in Stable Dialysis Patients | - | - |
FG-4592 | Phase 3 | Anemia in Chronic Kidney Disease | - | - |
SEPO® | Phase 3 | Chemotherapy Induced Anemia | - | - |
Roxadustat | Phase 3 | Chronic Kidney Disease | - | - |
Pamrevlumab | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
FG2216 | Phase 2 | Renal Anemia | - | - |
FG-3019 | Phase 2 | Pancreatic Cancer (Unresectable) | - | - |
Oral Iron | Phase 2 | Dialysis | - | - |
FG-3246 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |